Will radiation capitalise on its lead over drug-coated stents?
This article was originally published in Clinica
Executive Summary
Drug-coated stents and intravascular brachytherapy products are set to battle it out for market dominance over the next few years. But radiation devices will have the advantage of reaching the market first. That was the clear view of US Bancorp Piper Jaffray analyst Scott Davidson speaking at his company's annual healthcare conference in New York last month. He went on to predict the main developments and controversies expected during the year.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.